InterHealth FASEB Presentation on Super Citrimax Hydroxycitrate (HCA) Confirms Glykon Patents

InterHealth-sponsored research confirms Glykon US Patents covering HCA’s blood sugar and insulin regulation benefits.

Las Vegas, NV (PRWEB) June 29, 2006 -- At the Annual Meeting of the Federation of American Societies of Experimental Biology (FASEB) (1), researchers confirmed Glykon patents on blood sugar regulation and insulin metabolism.

In genetically obese rats given Super CitriMax® (200 mg/kg/day in drinking water) or placebo for 6-7 weeks, plasma insulin was reduced by 25% and insulin resistance by 16%. Previously at the 46th American College of Nutrition Annual Meeting (2), Glykon presented research performed at Georgetown University Medical School that showed effects of roughly twice this magnitude using only approximately 120 mg/kg/day of potassium and potassium-magnesium hydroxycitrate. Potassium and potassium-magnesium HCA dramatically improved insulin sensitivity and lowered serum insulin, but potassium-calcium HCA showed no such benefits at this lower intake. The weaker showing of potassium-calcium HCA in most areas may be the result of limited assimilation due to the presence of calcium and also the presence of the undesirable HCA lactone. Dutch scientists have published similar results regarding potassium-calcium HCA and suggested that there are wide differences in the physiologic benefits of the HCA salts being marketed. (3, 4)

Work from Europe based on Super CitriMax previously had indicated a lack of benefit to insulin levels. (5) Glykon in US Patent 6,476,071 reported that rats on a high fat diet received no weight control benefits from potassium-calcium HCA, whereas potassium hydroxycitrate strongly reduced weight gain and insulin levels. Only Glykon holds the rights to make claims regarding the impact of HCA on the regulation of insulin and blood sugar, modulation of leptin and glucocorticoids, improvements in bone mineralization, the regulation of immune function, normalization of blood pressure and control of inflammation.

On February 4, 2005, Glykon terminated its licensing agreement with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxyciticric acid and related products.


For more details contact:
Glykon Technologies Group, LLC
20885 Redwood Road #325
Castro Valley CA. 94546
Visit Glykon Technologies Group, LLC on the web at http://www.glykon.com

# # #
Contact Information
William Matheny
Glykon Technologies Group, LLC
http://www.glykon.com
510-583-9050

Online Web 2.0 Version
You can read the online version of this press release [here](#).